Post on 19-Dec-2014
description
IDPS
IDPS
The value of reducing The value of reducing blood pressure in the blood pressure in the
secondary prevention of secondary prevention of strokestroke
BackgroundBackground
IDPS
BACKGROUND:BACKGROUND: Blood pressure and secondary stroke Blood pressure and secondary stroke
incidenceincidence
4.004.00
2.002.00
1.001.00
0.500.50
0.250.25
7575 8080 8585 9090 9595
Usual diastolic BP (mm Hg)Usual diastolic BP (mm Hg)
Relative risk Relative risk ofof
strokestroke 4.004.00
2.002.00
1.001.00
0.500.50
0.250.25
Relative risk Relative risk ofof
strokestroke
Usual systolic BP (mm Hg)Usual systolic BP (mm Hg)
120120 130130 140140 150150 160160 170170
UKTIA 2435 patientsUKTIA 2435 patients
IDPS
Main results on stroke, Main results on stroke, cardiac events, dementia, cardiac events, dementia,
and cognitive functionand cognitive function
IDPS
AIMAIM
To determine the balance of benefits and risks conferred by an ACE inhibitor (perindopril)-based blood pressure-lowering regimen among patients with a history of cerebrovascular disease and a wide range of blood pressures at entry.
IDPS
In the past 5 years: cerebral hemorrhage
ischemic stroke
stroke of unknown type
TIA or amaurosis fugax
No major disability
No entry blood pressure criteria
Selection criteriaSelection criteria
IDPS
On top of their previous medication On top of their previous medication (including other BP-(including other BP-lowering agents)lowering agents)
ACERTIL 4 mg ACERTIL 4 mg ±± indapamide* indapamide* (2 or 2.5 mg)(2 or 2.5 mg)
Matching placebo(s)Matching placebo(s)
ACERTIL, ACERTIL ACERTIL, ACERTIL 2 mg 4 mg2 mg 4 mg
NB; mono or bi therapy at the discretion of the physician
MethodologyMethodology
IDPS
Primary Total strokeTotal stroke
Secondary Fatal or disabling stroke
Major vascular events (nonfatal stroke,
nonfatal MI, vascular death)
Dementia (DSM IV) and cognitive function
Disability and dependency
Study outcomesStudy outcomes
IDPS
Japan33
centers
Australia16 centers
New Zealand9 centers
Italy17
centers
France24
centers
Sweden23 centers
Belgium2
centers
UK and Ireland
23 centers
China26
centers
10 10 countriescountries172 centers172 centers
IDPS
Patient flowPatient flow
484 484 ineligibleineligible532 532 withdrewwithdrew
3051 3051 assigned assigned
activeactive
3054 assigned3054 assignedplaceboplacebo
61056105 patients patients randomizedrandomized
7121 pati7121 patients ents rregisteredegistered
3049 vital 3049 vital status knownstatus known
3053 vital 3053 vital status knownstatus known
Reference: Lancet. 2001;358:1033-1041.
IDPS
Demographics Female sex (%) 30 30 Age (y) 64 64 Asian ethnicity (%) 39 39
Blood pressure Systolic (mm Hg) 147 147 Diastolic (mm Hg) 86 86 Hypertension (%) 48 48
Cerebrovascular history Cerebral hemorrhage (%) 11 11 Cerebral infarction (%) 71 71 Stroke type unknown (%) 4 5 TIA/amaurosis fugax (%) 23 23
Baseline characteristicsBaseline characteristics
Active*Active* PlaceboPlacebo(n = 3051)(n = 3051) (n = 3054) (n = 3054)
Reference: Lancet. 2001;358:1033-1041.
* Active treatment: Coversyl 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
IDPS
† SBP 160 mm Hg or DBP 90 mm HgReference: Lancet . 2001;358:1033-1041.
Characteristic
Coversyl armPlacebo
Other medical history (%)
Current smoker 20 20
Diabetes 13 12
Coronary heart disease 16 16
Blood pressure and hypertension status
Mean systolic blood pressure, mm Hg (SD)
147 (19)
147 (19)
M
ean diastolic blood pressure, mm Hg (SD)
86 (11)
86 (11)
Hypertension (%)
†
48
48
Antihypertensive therapy (%)
50
51
Baseline characteristicsBaseline characteristics
IDPS
Adherence during follow-upAdherence during follow-up
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30 36 42 48Follow-up (mo)
Ad
he
ren
ce
PlaceboActive
Average adherenceAverage adherence
Active* 87%Active* 87%
Placebo 88%Placebo 88%
PP=0.07 =0.07
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
Safety and tolerabilitySafety and tolerability
ACERTIL-based therapy was very well tolerated:
Similar rate of withdrawalrate of withdrawal
• from activeactive therapy and placebo
• in hypertensivehypertensive and nonhypertensive patients
Few withdrawals for hypotension or cough
Reference: Lancet. 2001; 358:1033-1041.
IDPS
Blood pressure differences Blood pressure differences All participantsAll participants
60
80
100
120
140
160
B R 1 3 6 9 12 18 24 30 36 42 48 54
Follow-up (mo)
Blo
od
pre
ssu
re (
mm
Hg
)
Mean BP differenceMean BP difference
9.09.0//4.0 mm Hg4.0 mm HgActive *
Placebo
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
Mean BP reductionsMean BP reductions
HypertensiveNonhypertensive
CombinationSingle drug
All participants
SBP (SE)SBP (SE) DBP (SE) DBP (SE)
9.7 (0.4) 4.0 (0.3) 8.4 (0.4) 4.1 (0.2)
11.8 (0.4) 4.8 (0.3) 5.2 (0.4) 2.8 (0.3)
9.0 (0.3) 4.0 (0.2)
Reference: Lancet. 2001;358:1033-1041.
IDPS
Results on stroke Results on stroke outcomesoutcomes
IDPS
Follow-up time (y)
Pro
port
ion
wit
h e
ven
t Placebo
Active*
0.20
0.15
0.10
0.05
0.000 1 2 3 4
28% 28% risk risk reductionreduction
95% CI 17 - 38%
PP<0.0001<0.0001
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
StrokeStrokeAll participantsAll participants
Reference: Lancet. 2001;358:1033-1041.
IDPS
Stroke severity and subtypeStroke severity and subtypeAll participantsAll participants
0.62 (0.48-0.80)
0.74 (0.61-0.90)
0.76 (0.65-0.90)
0.50 (0.33-0.74)
0.82 (0.55-1.24)
0.72 (0.62-0.83)
0.5 2.0 Hazard ratio
1.0
Strokes Active* Placebo
93
179
246
37
42
307
149
238
319
74
51
420
Favorsactive
Favorsplacebo
Hazard ratio
(95%CI)
•Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg(or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
• Fatal/disabling
• Other stroke
• Cerebral infarction
• Cerebral hemorrhage
• Stroke type unknown
• Total
IDPS
Stroke by medical historyStroke by medical historyAll participantsAll participants
Hypertensive 163 235
Not hypertensive 144 185
Diabetes 48 65
No diabetes 259 355
Cerebral infarction 236 307
Cerebral hemorrhage 28 49
TIA/amaurosis 33 49
Total 307 420
Hazard ratio(95%CI)
Hazard ratio0.5 2.01.0
Strokes Active* Placebo
Favorsactive
Favorsplacebo
0.67 (0.55-0.81)0.73 (0.58-0.92)
0.67 (0.46-0.98)0.72 (0.62-0.85)
0.76 (0.64-0.90)0.52 (0.33-0.83)0.66 (0.42-1.02)
0.72 (0.62-0.83)
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
IndicationsIndications
Treatment Treatment should be consideredshould be considered for for patients with cerebrovascular disease, patients with cerebrovascular disease, irrespective ofirrespective of::
Type of stroke or TIA Initial BP (hypertensive or nonhypertensive) Other drugs and treatments Region/ ethnicity Age and gender
Reference: Lancet. 2001;358:1033-1041.
IDPS
ResultsResults onon
cardiac outcomescardiac outcomes
IDPS
Major vascular eventsMajor vascular events All participants
Hazard ratio(95%CI)
Vascular death
Nonfatal MI
Nonfatal stroke
TotalTotal
Hazard Ratio
Events Active* Placebo
Favorsactive
Favorsplacebo
0.4 1.0 2.0
181
60
275
458
198
96
380
604
0.91 (0.75-1.12)
0.62 (0.45-0.86)
0.71 (0.61-0.83)
0.74 (0.66-0.84)
•Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
Major vascular eventsMajor vascular events
Follow-up time (y)PROGRESS Coll. Group Eur Heart J. 2003 24: 475-484
1 2 3 4
*
Pro
port
ion w
ith e
vent
0.05
0.10
0.15
0.20
0.2526%26% risk reduction
(95% CI 16-33%)PP<0.0001<0.0001
PlaceboActive*
IDPS
Follow-up time (y)•Active treatment: Coversyl 4 mg +/- indapamide 2.5 mg •(or 2 mg in Japan)
26%26% risk reduction
95% CI 6-42%PP = 0.01 = 0.0166
PlaceboActiveP
roport
ion w
ith e
vent
0.01
0.02
0.03
0.04
0.05
0.06
1 2 3 4
*
Major coronary eventsMajor coronary events(CHD death or nonfatal myocardial infarction)
Reference: Lancet. 2001;358:1033-1041.
IDPS
0.00
0.05
0.10
0 1 2 3 4
21% risk reduction21% risk reduction(95%CI 6-33%)P value = 0.008
Follow-up time (y)
Pro
port
ion w
ith e
vent
Placebo
Active
Total coronary eventsTotal coronary events(CHD death, nonfatal MI,
coronary revascularization, unstable angina,
IDPS
Heart failureHeart failure(Death, hospitalization, or discontinuation)(Death, hospitalization, or discontinuation)
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
0.00
0.01
0.02
0.03
0.04
0.05
0.06
0 1 2 3 4
Placebo
Active
26%26% risk reduction(95%CI 5-42%)PP value = 0.01 value = 0.01
Follow-up time (y)
Pro
port
ion
with
eve
nt
*
Reference: Eur Heart J. In press.
*
IDPS
Comments and perspectivesComments and perspectives
IDPS
Why the difference betweensingle-drug therapysingle-drug therapy (ACERTIL
alone) and combination therapycombination therapy(ACERTIL plus indapamide)?
IssueIssue
IDPS
Combination therapy (12/5 mm Hg) Combination therapy (12/5 mm Hg) and single-drug therapy (5/3 mm Hg) and single-drug therapy (5/3 mm Hg)
Hazard ratio
Combination
Single drug
Total
Combination
Single drug
TotalTotal
Stroke
Major vascular events
Events Active* Placebo
Favorsactive
Favorsplacebo
Risk reduction(95%CI)
0.5 2.01.0
150157307
231
227
458
255165420
367
237
604
43% (30 43% (30 to 54%) to 54%)
5% (-19 to 23%)5% (-19 to 23%)
28% (17 to 38%)28% (17 to 38%)
40% (29 to 49%)40% (29 to 49%)
4% (-15 to 20%)4% (-15 to 20%)
26% (16 to 26% (16 to
34%)34%)Tests for homogeneity (combination vs single drug): both < 0.001
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
DemographicDemographic Female sex (%) 29 3232 Age (years)* 63 6565 Asian ethnicity (%) 38 3939
Blood pressureBlood pressure Systolic (mm Hg)* 149 144144 Diastolic (mm Hg)* 87 8484 Hypertension (%)* 54 4040
Baseline characteristicsBaseline characteristics
Combination therapyCombination therapySingle drug Single drug therapytherapy (n = 3544) (n = 3544) (n = 2561)(n = 2561)
Reference: Lancet. 2001;358:1033-1041.
IDPS
IssueIssue
• Study not designed to detectdesigned to detect
• Study not powered to detectpowered to detect / Number of
subjects too small
• Effect not proven or disproven (Wide CI)
• Differences in patients’ baseline characteristics
Why no detectable effect with ACERTIL alone?Why no detectable effect with ACERTIL alone?
IDPS
Is it safe to lower Is it safe to lower blood pressure, post-blood pressure, post-
stroke, stroke, especially in normotensive especially in normotensive
subjects?subjects?
IssueIssue
IDPS
Adherence during follow-upAdherence during follow-up
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30 36 42 48Follow-up (mo)
Ad
he
ren
ce
PlaceboActive
Average adherenceAverage adherence
Active* 87%Active* 87%
Placebo 88%Placebo 88%
PP=0.07 =0.07
* Active treatment: ACERTIL 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Lancet. 2001;358:1033-1041.
IDPS
Results on Results on dementia and dementia and
cognitive decline cognitive decline outcomeoutcome
IDPS
Stroke and dementiaStroke and dementia
• Stroke is the leading cause of disability in adults1
• Cerebrovascular disease is the second most common cause of dementia2
• Vascular dementia is one of the rare preventable dementias3
1. Barba R et al. Previous and incident dementia as risk factors for mortality in stroke patients. Stroke. 2002;33:1993-1998.2. Leys D et al. Epidemiology of vascular dementia. Hemostasis. 1998;28:134-150.3. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet. 1992;340:654-648.
IDPS
Major types of dementiaMajor types of dementia
• Alzheimer’s disease Alzheimer’s disease 53.7%53.7%
• Vascular dementiaVascular dementia 15.8%15.8%11
single or multiple infarcts2
small-vessel disease2 hypoperfusion2
hemorrhage2
1. Lobo A et al. Neurology. 2000;54(suppl 5):S4-S9.2. Gold G. Les démences vasculaires. Med Hyg. 2002;60:1165-1167.
IDPS
The cumulative incidence of The cumulative incidence of dementia after strokedementia after stroke
0
5
10
15
20
25
Incidence of dementia (%)
7%
10%
15%
23%
Timel (y)1 3 5 10
Incident of stroke increase the risk of dementia by 140%
Lobo A et al. Neurology. 2000;54(suppl 5):S4-S9.
IDPS
Prevalence of vascular dementia in men Prevalence of vascular dementia in men and women in European countriesand women in European countries
Lobo A et al. Neurology. 2000;54(suppl 5):S4-S9.
0
2
4
6
65-69 70-74 75-79 80-84 85-89 90+
WomenMen
Age (y)
Cases/1
00 o
f p
op
ula
tion
IDPS
2222ApoE4 allele carrier (%)
1515MMSE < 26 (%)
29 (27-30)
29 (27-30)
Median MMSE score
3939Asian (%)
3030Female (%)
64 (10)64 (10)Age, y (SD)
Baseline characteristicsBaseline characteristics
Active Placebo(n = 3051) (n = 3054)
• 6105 patients with stroke or TIA• FU 3.9 years• MMSE / Screening for dementia each year
PROGRESS Coll Group Arch Int Med. 2003; 163:1069-1075
IDPS
DementiaDementia1. Screening
MMSE <26Questions about dementiaMMSE missing
2. DiagnosisSpecialist in each center; DSM-IV criteriaDiagnosis reviewed centrally
Cognitive declineCognitive decline = drop of 3pts or more of MMSE during FU
Cognitive outcomesCognitive outcomes
Reference: Arch Int Med. In press.
IDPS
Cognitive outcomes (ctd.)Cognitive outcomes (ctd.)
• Dementia 1580 patients screened positive during FU Expert assessment for 98% 410 patients demented 108 preceded by a recurrent stroke
• Cognitive decline 610 patients (25 per 1000 PY)
Reference: Arch Int Med. In press.
IDPS
Effect of treatment on dementiaEffect of treatment on dementia
Post-stroke
Without stroke
Dementia
Total
Events Active* Placebo
Favorsactive
Favorsplacebo
Risk reduction(95%CI)
43
150
193
65
152
217
34% (3 to 55%)
1% (-24 to 22%)
12% (-8 to 28%)
0.5 2.0 Odds ratio
1.0
* Active treatment: Coversyl 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Arch Int Med. In press.
IDPS
With stroke
Without stroke
Total
48
228
276
86
248
334
45% (21 to 61%)
9% (-10 to 84%)
19% (4 to 32%)
Effect of treatment on cognitive Effect of treatment on cognitive declinedecline
Events Active* Placebo
Favorsactive
Favorsplacebo
Risk reduction(95%CI)
Cognitive decline
0.5 2.0 Odds ratio
1.0
* Active treatment: Coversyl 4 mg +/- indapamide 2.5 mg (or 2 mg in Japan)
Reference: Arch Int Med. In press.
IDPS
ConclusionConclusionConclusionConclusion
• 28%28% reduction in the all strokes
• 50% 50% reduction in the risk of hemorrhagic stroke
• 25%25% reduction in the risk of cerebral ischemia
Reference: Lancet . 2001;358:1033-1041
IDPS
• 26%26% reduction in the risk of major cardiovascular events
• 26%26% reduction in the risk of major coronary events
• 33%33% reduction in myocardial infarction
• All benefits achieved against a background of standard care that included antiplatelet and antihypertensive therapy
Reference: Lancet . 2001;358:1033-1041.
ConclusionConclusionConclusionConclusion
IDPS
Recommendations for initiationRecommendations for initiation
Acute strokeAcute strokeInitiate treatment at the time of discharge orpost-discharge follow up
History of stroke or TIAHistory of stroke or TIAPrimary care physician to initiate treatment at the patient’s next visit
IDPS
ACERTIL offers optimal ACERTIL offers optimal
cardiovascular protectioncardiovascular protection
in all hypertensive patientsin all hypertensive patients